| ID Source | ID |
|---|---|
| PubMed CID | 163103 |
| MeSH ID | M0080978 |
| Synonym |
|---|
| technetium tc 99m (sn)methylenediphosphonate |
| 66138-58-7 |
| tc-99m-(sn)methylenediphosphonate |
| tc-99m-sn-mdp |
| tc-99m-technetium-tin-methylene-diphosphonate |
| phosphonic acid, methylenebis-, technetium(4 )-99tc tin(2 ) salt |
| tc-99m-sn-medronate |
| technetium(4+)-(99)tc tin(2+)methylenebis-phosphonic acid salt |
| phosphonomethylphosphonic acid;technetium-99(4+);tin(2+) |
| Excerpt | Relevance | Reference |
|---|---|---|
| "3% (S)-ketoprofen demonstrated a reduction and other groups demonstrated elevations over the 60-day dosing period." | ( Enantiospecific inhibition of ligature-induced periodontitis in beagles with topical (S)-ketoprofen. Fiorellini, JP; Howell, TH; Martuscelli, G; McCullough, JR; Oringer, RJ; Paquette, DW; Reasner, DS; Williams, RC, 1997) | 0.3 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 37 (78.72) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (7.55%) | 5.53% |
| Reviews | 2 (3.77%) | 6.00% |
| Case Studies | 4 (7.55%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 43 (81.13%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium. | 2.36 | 2 | 0 | pentacarboxylic acid | copper chelator |
| etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces. | 1.97 | 1 | 0 | 1,1-bis(phosphonic acid) | antineoplastic agent; bone density conservation agent; chelator |
| flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain. | 1.96 | 1 | 0 | fluorobiphenyl; monocarboxylic acid | antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug |
| ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. | 1.99 | 1 | 0 | benzophenones; oxo monocarboxylic acid | antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic |
| sodium fluoride [no description available] | 1.97 | 1 | 0 | fluoride salt | mutagen |
| mercury Mercury: A silver metallic element that exists as a liquid at room temperature. It has the atomic symbol Hg (from hydrargyrum, liquid silver), atomic number 80, and atomic weight 200.59. Mercury is used in many industrial applications and its salts have been employed therapeutically as purgatives, antisyphilitics, disinfectants, and astringents. It can be absorbed through the skin and mucous membranes which leads to MERCURY POISONING. Because of its toxicity, the clinical use of mercury and mercurials is diminishing.. mercury(0) : Elemental mercury of oxidation state zero. | 1.96 | 1 | 0 | elemental mercury; zinc group element atom | neurotoxin |
| technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years. | 5.87 | 24 | 1 | manganese group element atom | |
| calcium phosphate, dibasic, anhydrous calcium phosphate, dibasic, anhydrous: molecular formula CaHPO(4), DCPA=dicalcium phosphate anhydrous; don't confuse with dichloropropionanilide which also is called DCPA; MW=136.06; has greater surface area and lower pH than DCPD (dicalcium phosphate dihydrate); occurs in nature as monetite; an intermediate in preparing hydroxyapatite | 1.97 | 1 | 0 | calcium phosphate | |
| calcium phosphate, monobasic, anhydrous calcium phosphate, monobasic: MW 234.05 | 1.97 | 1 | 0 | calcium phosphate | fertilizer |
| tricalcium phosphate tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues. | 1.97 | 1 | 0 | calcium phosphate | |
| mercuric iodide, red mercuric iodide, red: single cyrstals of HgI2 are used as room temp semiconductor x-ray detectors for application to computed tomography. mercury diiodide : A mercury coordination entity composed of mercury and iodine with formula HgI2. | 1.96 | 1 | 0 | mercury coordination entity | |
| iodine [no description available] | 1.96 | 1 | 0 | halide anion; monoatomic iodine | human metabolite |
| 6-o-stearoyl-n-acetylmuramyl-alanylisoglutamine [no description available] | 3.38 | 1 | 1 | ||
| calcium pyrophosphate [no description available] | 1.97 | 1 | 0 | ||
| technetium tc 99m pentetate Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents. | 2.36 | 2 | 0 | ||
| dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | 1.96 | 1 | 0 | actinomycin | mutagen |
| tin [no description available] | 4.6 | 6 | 1 | carbon group element atom; elemental tin; metal atom | micronutrient |
| sulfur Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine. | 1.96 | 1 | 0 | chalcogen; nonmetal atom | macronutrient |
| strontium radioisotopes Strontium Radioisotopes: Unstable isotopes of strontium that decay or disintegrate spontaneously emitting radiation. Sr 80-83, 85, and 89-95 are radioactive strontium isotopes. | 1.95 | 1 | 0 | ||
| technetium tc 99m stannous pyrophosphate [no description available] | 4.26 | 4 | 1 | ||
| technetium tc 99m pyrophosphate Technetium Tc 99m Pyrophosphate: A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities. | 4.26 | 4 | 1 | ||
| sodium pertechnetate tc 99m Sodium Pertechnetate Tc 99m: A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, cardiovascular and cerebral circulation, brain, thyroid, and joints. | 1.96 | 1 | 0 | ||
| tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria. | 1.96 | 1 | 0 | ||
| technetium tc 99m sulfur colloid Technetium Tc 99m Sulfur Colloid: A gamma-emitting radionuclide imaging agent used for the diagnosis of diseases in many tissues, particularly in the gastrointestinal system, liver, and spleen. | 1.96 | 1 | 0 | ||
| technetium tc 99m medronate Technetium Tc 99m Medronate: A gamma-emitting radionuclide imaging agent used primarily in skeletal scintigraphy. Because of its absorption by a variety of tumors, it is useful for the detection of neoplasms. | 9.06 | 47 | 3 |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Coxa Plana [description not available] | 0 | 1.96 | 1 | 0 |
| Aseptic Necrosis of Femur Head [description not available] | 0 | 1.96 | 1 | 0 |
| CKD-MBD [description not available] | 0 | 1.96 | 1 | 0 |
| Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. | 0 | 1.96 | 1 | 0 |
| Dermatomyositis, Adult Type [description not available] | 0 | 1.96 | 1 | 0 |
| Dermatomyositis A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) | 0 | 1.96 | 1 | 0 |
| Bone Loss, Osteoclastic [description not available] | 0 | 3.98 | 5 | 0 |
| Parodontosis [description not available] | 0 | 2.65 | 3 | 0 |
| Periodontal Diseases Pathological processes involving the PERIODONTIUM including the gum (GINGIVA), the alveolar bone (ALVEOLAR PROCESS), the DENTAL CEMENTUM, and the PERIODONTAL LIGAMENT. | 0 | 2.65 | 3 | 0 |
| Cancer of Head [description not available] | 0 | 1.96 | 1 | 0 |
| Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) | 0 | 1.96 | 1 | 0 |
| Bone Cancer [description not available] | 0 | 4.27 | 4 | 1 |
| Cancer of Lung [description not available] | 0 | 1.96 | 1 | 0 |
| Lymph Node Metastasis [description not available] | 0 | 1.96 | 1 | 0 |
| Osteogenic Sarcoma [description not available] | 0 | 2.37 | 2 | 0 |
| Femoral Neoplasms New abnormal growth of tissue in the FEMUR. | 0 | 1.96 | 1 | 0 |
| Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. | 0 | 4.27 | 4 | 1 |
| Lung Neoplasms Tumors or cancer of the LUNG. | 0 | 1.96 | 1 | 0 |
| Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) | 0 | 2.37 | 2 | 0 |
| Arthritis, Degenerative [description not available] | 0 | 1.96 | 1 | 0 |
| Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans. | 0 | 1.96 | 1 | 0 |
| Coronary Heart Disease [description not available] | 0 | 1.96 | 1 | 0 |
| Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. | 0 | 1.96 | 1 | 0 |
| Chronic Kidney Failure [description not available] | 0 | 1.95 | 1 | 0 |
| Cirrhosis, Liver [description not available] | 0 | 1.95 | 1 | 0 |
| Osseous Paget's Disease [description not available] | 0 | 1.95 | 1 | 0 |
| Adult Rickets [description not available] | 0 | 1.95 | 1 | 0 |
| Age-Related Osteoporosis [description not available] | 0 | 2.37 | 2 | 0 |
| Bone Diseases Diseases of BONES. | 0 | 2.36 | 2 | 0 |
| Hyperparathyroidism A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES. | 0 | 1.95 | 1 | 0 |
| Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. | 0 | 1.95 | 1 | 0 |
| Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. | 0 | 1.95 | 1 | 0 |
| Osteitis Deformans A disease marked by repeated episodes of increased bone resorption followed by excessive attempts at repair, resulting in weakened, deformed bones of increased mass. The resultant architecture of the bone assumes a mosaic pattern in which the fibers take on a haphazard pattern instead of the normal parallel symmetry. | 0 | 1.95 | 1 | 0 |
| Osteomalacia Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis. | 0 | 1.95 | 1 | 0 |
| Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. | 0 | 2.37 | 2 | 0 |
| Polyarthritis [description not available] | 0 | 1.96 | 1 | 0 |
| Arthritis Acute or chronic inflammation of JOINTS. | 0 | 1.96 | 1 | 0 |
| Uveitis, Anterior Inflammation of the anterior uvea comprising the iris, angle structures, and the ciliary body. Manifestations of this disorder include ciliary injection, exudation into the anterior chamber, iris changes, and adhesions between the iris and lens (posterior synechiae). Intraocular pressure may be increased or reduced. | 0 | 1.96 | 1 | 0 |
| Angiogenesis, Pathologic [description not available] | 0 | 2.9 | 1 | 0 |
| Aseptic Necrosis of Bone [description not available] | 0 | 2.9 | 1 | 0 |
| Meniscitis [description not available] | 0 | 2.9 | 1 | 0 |
| Osteonecrosis Death of a bone or part of a bone, either atraumatic or posttraumatic. | 0 | 2.9 | 1 | 0 |
| Innate Inflammatory Response [description not available] | 0 | 1.98 | 1 | 0 |
| Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. | 0 | 1.98 | 1 | 0 |
| Adenocarcinoma Of Kidney [description not available] | 0 | 1.98 | 1 | 0 |
| Cancer of Kidney [description not available] | 0 | 1.98 | 1 | 0 |
| Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. | 0 | 1.98 | 1 | 0 |
| Kidney Neoplasms Tumors or cancers of the KIDNEY. | 0 | 1.98 | 1 | 0 |
| Disease Exacerbation [description not available] | 0 | 1.99 | 1 | 0 |
| Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. | 0 | 1.99 | 1 | 0 |
| Pericementitis [description not available] | 0 | 1.99 | 1 | 0 |
| Alveolar Bone Atrophy [description not available] | 0 | 1.99 | 1 | 0 |
| Periodontitis Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology) | 0 | 1.99 | 1 | 0 |
| Cystic Angiomatosis Of Bone, Diffuse [description not available] | 0 | 2.91 | 1 | 0 |
| Cancer of Prostate [description not available] | 0 | 3.38 | 1 | 1 |
| Prostatic Neoplasms Tumors or cancer of the PROSTATE. | 0 | 3.38 | 1 | 1 |
| Chronic Illness [description not available] | 0 | 3.38 | 1 | 1 |
| Mandibular Diseases Diseases involving the MANDIBLE. | 0 | 3.38 | 1 | 1 |
| Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). | 0 | 3.38 | 1 | 1 |
| Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA. | 0 | 3.38 | 1 | 1 |
| Thalassemias [description not available] | 0 | 2.37 | 2 | 0 |
| Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. | 0 | 2.37 | 2 | 0 |
| Cardiovascular Stroke [description not available] | 0 | 3.35 | 1 | 1 |
| Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). | 0 | 3.35 | 1 | 1 |